5/22/2019  5:31:29 PM Chg. +0.57 Volume Bid5:31:29 PM Ask7:47:45 PM Market Capitalization Dividend Y. P/E Ratio
84.18CHF +0.68% 4.25 mill.
Turnover: 236.06 mill.
84.15Bid Size: 120 84.15Ask Size: 14 195.7 bill.CHF - -

Business description

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
 

Management board & Supervisory board

CEO
Vasant Narasimhan
Management board
Harry Kirsch, Bertrand Bodson, Dr. James E. Bradner, John Tsai, Klaus Moosmayer, Paul Hudson, Robert Weltevreden, Shannon Thyme Klinger, Steffen Lang, Steven Baert, Susanne Schaffert
Supervisory board
Dr. Joerg Reinhardt, Ann Fudge, Charles L. Sawyers, Dr. Andreas von Planta, Dr. Charlotte Pamer-Wieser, Dr. Enrico Vanni, Dr. Nancy C. Andrews, Dr. Srikant Datar, Elizabeth Doherty, Frans van Houten, Patrice Bula, Ton Buechner, William T. Winters
 

Company data

Name: Novartis AG
Address: Lichtstrasse 35,CH-4002 Basel
Phone: +41-61-324-1111
Fax: +41-61-324-8001
E-mail: -
Internet: www.novartis.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 92.00%
IPO date: 1/1/1996

Investor relations

Name: Samir Shah
IR phone: +41-61-324-7944
IR-Fax: -
IR e-mail: investor.relations@n...tis.com investor.relations@novartis.com

Company calendar

CW 29 | 7/18/2019 Interim Report 2nd Quarter/6 Months
CW 43 | 10/22/2019 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
92.00%
Emasan AG
 
3.50%
Novartis Foundation for Employee Participation
 
2.30%
UBS Fund Management
 
2.20%